Mastopathy Myths and Reality: Good Choice for Pharm Industry?

Мастопатия мифы и реальность: удачный выбор для фарм индустрии?
Gulbarshin Darisheva 1, Bolat Saktashev 1, Aigul Brimova 1
More Detail
1 Gynecological Diseases Department, Corporate Foundation “University Medical Center” Astana, Republic of Kazakhstan
J CLIN MED KAZ, Volume 3, Issue 49, pp. 28-31. https://doi.org/10.23950/1812-2892-JCMK-00581
OPEN ACCESS 3572 Views 3188 Downloads
Download Full Text (PDF)

ABSTRACT

This article is devoted to the problem of mastopathy in the post-Soviet space. Analysis of clinical observation, literature data shows a different approach in describing this condition, methods of diagnosis and treatment. Often, a purposeful motivational assignment of certain groups of drugs from biologically active food supplements, iodine preparations to the administration of antiestrogens, etc. is often used to correct this condition. This problem requires a careful approach to etymology, diagnosis and principles of conducting similar processes.
Keywords: mastopathy, breast, antiestrogens, BIRADS system, breast cancer

CITATION

Darisheva G, Saktashev B, Brimova A. Mastopathy Myths and Reality: Good Choice for Pharm Industry?. Journal of Clinical Medicine of Kazakhstan. 2018;3(49):28-31. https://doi.org/10.23950/1812-2892-JCMK-00581

REFERENCES

  • Letyagin V.P. Mastopatiya (Mastopathy) [in Russian]. 2000;8(11):468-472.
  • Susan L. Norwoord. Fibrocystic Breast Disease An Update and Review. Journal of Obstetric Gynecologic, & Neonatal Nursing. 1990;19:116-121
  • Ghent W.R., Eskin B.A., Low D.A,. Hill L.P. Iodine replacement in the fibrocystic disease of the breast. Canadian Journal of Surgery. 1993;36(5):453-60.
  • Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1229-1231.
  • A Short Guide to the European guidelines for quality assurance in breast cancer screening and diagnosis. The European Breast Cancer Coalition. 2010;4:2-17. 
  • Aebi S., Davidson T., Gruber G. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2010;21(5);10-14.
  • Sardanelli F. et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. European journal of cancer. 2010;46(8):1296-1316.
  • American College of Radiology. ACR practice guideline for the performance of contrast enhanced magnetic resonance imaging of the breast 2018. Available at: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf. Accessed October 14, 2018.
  • Mercado CL. BI-RADS Update. Radiologic Clinics. 2014;52(3):481-7.
  • Olawaiye A., Withiam-Leitch M., Danakas G., Kahn K. Mastalgia: a review of management. J. Reprod. Med. 2005;50(12):933- 939.
  • Svyatkina A.A., Yeliseyev N.P. O nekotoryh osobennostjah raspredelenija funkcional’nyh blokad pozvonochnika pri fibrokistoznoj mastopatii (About Some features of the spine functional blockages distribution in fibrocystic mastopathy). Journal of Manual Therapy. 2008;3(31).
  • Stöppler MC, Shiel Jr. WC. Fibrocystic Breast Condition (Cysts, Fibrosis, Lumps, Changes) Symptoms, Diet, Treatment Center. Accessed on 3/19/2018. Available at: https://www.medicinenet.com/fibrocystic_breast_condition/article.htm
  • Masciadria N., Ferrantib C. Benign breast lesions: Ultrasound. J Ultrasound. 2011;14(2):55-65 doi: 10.1016/j.jus.2011.03.002
  • Vaidyanathan L., Barnard K., Elnicki D.M. Benign Breast Disease: When To Treat, When To Reassure, When To Refer. Cleveland Clinic Journal of Medicine. 2002;69:424-439.
  • American Cancer Society. Types of non-cancerous breast conditions. Available at: https://www.cancer.org/cancer/breast-cancer/ non-cancerous-breast-conditions.html Accessed October 14, 2018.
  • Sloane E. Biology of Women. New York: Delmar Cengage Learning; 2002. 200-201p.
  • Gadducci A., Guerrieri M.E., Genazzani A.R. Benign breast diseases, contraception and hormone replacement therapy. Minerva Ginecologica. 2012;64(1):67-74.
  • Stoddard I.I., Frederick R. Iodine Alters Gene Expression in the MCF7 Breast Cancer Cell Line: Evidence for an Anti-Estrogen Effect of Iodine. International Journal of Medical Sciences. 2008;5:189-96. doi:10.7150/ijms.5.189
  • Iodine: Fact Sheet for Health Professionals». NIH, The Office of Dietary Supplements. Available at: https://ods.od.nih.gov/ factsheets/Iodine-HealthProfessional. Accessed October 14, 2018.
  • Kessler J.H. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. The Breast Journal. (2004);10(4):328- 36. doi: 10.1111/j.1075122X.2004.21341.x.
  • Hartmann L.C ., Sellers T., Frost M.H., Lingle W.L., Degnim A.C., Ghosh K., Vierkant R.A. et al. Benign breast disease and the risk of breast cancer. New England Journal of Medicine. 2005;353(3):229-237. doi: 10.1056 / NEJMoa044383